IL268458A - Inhalable nicotine formulations, and methods of making and using thereof - Google Patents
Inhalable nicotine formulations, and methods of making and using thereofInfo
- Publication number
- IL268458A IL268458A IL268458A IL26845819A IL268458A IL 268458 A IL268458 A IL 268458A IL 268458 A IL268458 A IL 268458A IL 26845819 A IL26845819 A IL 26845819A IL 268458 A IL268458 A IL 268458A
- Authority
- IL
- Israel
- Prior art keywords
- making
- methods
- nicotine formulations
- inhalable nicotine
- inhalable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/452,133 US10149844B2 (en) | 2015-09-16 | 2017-03-07 | Inhalable nicotine formulations, and methods of making and using thereof |
PCT/IB2018/051482 WO2018163085A1 (en) | 2017-03-07 | 2018-03-07 | Inhalable nicotine formulations, and methods of making and using thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL268458A true IL268458A (en) | 2019-09-26 |
Family
ID=61731727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL268458A IL268458A (en) | 2017-03-07 | 2019-08-04 | Inhalable nicotine formulations, and methods of making and using thereof |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP3592352A1 (en) |
JP (1) | JP2020510002A (en) |
KR (1) | KR20190126772A (en) |
CN (1) | CN110300588A (en) |
CA (1) | CA3048677A1 (en) |
IL (1) | IL268458A (en) |
MX (1) | MX2019010263A (en) |
RU (1) | RU2770039C2 (en) |
WO (1) | WO2018163085A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL4057845T3 (en) * | 2019-11-14 | 2024-03-25 | Philip Morris Products S.A. | Improved tobacco flavoured dry powder formulation |
MX2023002465A (en) * | 2020-09-03 | 2023-03-23 | Philip Morris Products Sa | Freeze dried low hygroscopicity active powder compositions. |
CN112841709B (en) * | 2021-01-20 | 2022-11-25 | 深圳市艾普生物科技有限公司 | Preparation method and application of nicotine salt |
CN113880802A (en) * | 2021-11-09 | 2022-01-04 | 深圳萨特瓦生物科技有限公司 | Tartaric acid-nicotine salt, preparation method and application thereof, and preparation method of anhydrous tartaric acid crystal |
WO2024091005A1 (en) * | 2022-10-27 | 2024-05-02 | 주식회사 케이티앤지 | Dry powder inhaler stick containing cough suppressant and dry powder inhaler comprising same |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE145819T1 (en) * | 1992-03-10 | 1996-12-15 | Fisons Plc | INHALABLE MEDICINAL PRODUCTS |
GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
US7871598B1 (en) * | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
EP1309312A2 (en) * | 2000-08-07 | 2003-05-14 | Inhale Therapeutic Systems, Inc. | Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation |
WO2003024396A2 (en) * | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
ITMI20012174A1 (en) * | 2001-10-18 | 2003-04-18 | Univ Parma | POWDER FOR NASAL DRUG ADMINISTRATION |
GB0425758D0 (en) * | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
ITMI20051999A1 (en) * | 2005-10-21 | 2007-04-22 | Eratech S R L | INHALATION FORMULATIONS OF DRUGS IN DRY POWDER FOR ADMINISTRATION AS SUCH OR WITH NEBULIZER AND EQUIPPED WITH HIGH EROGABILITY RESPIRABILITY AND STABILITY |
GB0523576D0 (en) * | 2005-11-18 | 2005-12-28 | Theradeas Ltd | Drug composition and its use in therapy |
US7832397B2 (en) * | 2005-12-28 | 2010-11-16 | Philip Morris Usa Inc. | Aerosol powder delivery device |
WO2008069972A2 (en) * | 2006-12-01 | 2008-06-12 | Aradigm Corporation | Systems for effecting cessation of tobacco use |
US20140294969A1 (en) * | 2011-08-01 | 2014-10-02 | Monash University | Method and formulation for inhalation |
JP6672258B2 (en) * | 2014-04-08 | 2020-03-25 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | Nicotine preparation and method for producing the same |
FR3035826B1 (en) * | 2015-05-07 | 2018-11-16 | Saint-Gobain Glass France | VEHICLE GLAZING COMPRISING A PLATINUM FOR FASTENING MULTIPLE ACCESSORIES, PLATINUM AND FIXING METHOD. |
US9585835B1 (en) * | 2015-09-16 | 2017-03-07 | Sansa Corporation (Barbados) Inc. | Inhalable nicotine formulations and methods of making and using the same |
CN105770862B (en) * | 2016-04-22 | 2022-01-11 | 北京三元基因药业股份有限公司 | Dry powder inhalant of interferon |
MX2018015119A (en) * | 2016-06-30 | 2019-04-15 | Philip Morris Products Sa | Nicotine particles. |
-
2018
- 2018-03-07 MX MX2019010263A patent/MX2019010263A/en unknown
- 2018-03-07 CN CN201880011538.9A patent/CN110300588A/en active Pending
- 2018-03-07 CA CA3048677A patent/CA3048677A1/en not_active Abandoned
- 2018-03-07 EP EP18712467.2A patent/EP3592352A1/en active Pending
- 2018-03-07 RU RU2019128062A patent/RU2770039C2/en active
- 2018-03-07 JP JP2019544811A patent/JP2020510002A/en active Pending
- 2018-03-07 WO PCT/IB2018/051482 patent/WO2018163085A1/en active Application Filing
- 2018-03-07 KR KR1020197023058A patent/KR20190126772A/en not_active Application Discontinuation
-
2019
- 2019-08-04 IL IL268458A patent/IL268458A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110300588A (en) | 2019-10-01 |
JP2020510002A (en) | 2020-04-02 |
KR20190126772A (en) | 2019-11-12 |
RU2019128062A3 (en) | 2021-05-21 |
EP3592352A1 (en) | 2020-01-15 |
MX2019010263A (en) | 2019-10-09 |
RU2770039C2 (en) | 2022-04-14 |
RU2019128062A (en) | 2021-04-07 |
CA3048677A1 (en) | 2018-09-13 |
WO2018163085A1 (en) | 2018-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1258016A1 (en) | Inhalable nicotine formulations, and methods of making and using thereof | |
IL271736A (en) | Nicotine salts and methods of making and using same | |
HK1254525A1 (en) | Therapeutic compositions, combinations, and methods of use | |
PT3546457T (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
IL261469A (en) | Devices for evaporation and inhalation of nicotine | |
EP3129024A4 (en) | Nicotine formulations and methods of making the same | |
IL268458A (en) | Inhalable nicotine formulations, and methods of making and using thereof | |
GB201513932D0 (en) | Keratin treatment formulations and methods | |
IL261186A (en) | Nicotine formulation and aerosols | |
EP3283151A4 (en) | Dry powder inhaler and method of use | |
IL265870A (en) | Nanoparticle formulations and methods of making and using thereof | |
HK1259372A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
EP3423040A4 (en) | Microneedle particles, compositions, and methods of treatment and delivering a substance of interest | |
IL258139A (en) | Nicotine formulations and methods of making and using the same | |
PT3527552T (en) | Fused tricyclic -amino acid derivative, preparation method therefor, and medical use thereof | |
PL3373910T3 (en) | Echinomycin formulation, method of making and method of use thereof | |
IL265881A (en) | Inhaler and methods of use thereof | |
RS65120B1 (en) | Pharmaceutical formulations and methods of use thereof | |
IL266132B (en) | Pharmaceutical formulations and methods of making the same | |
EP3562446A4 (en) | Nasal implants and methods of use | |
HK1250205A1 (en) | Human milk compositions and methods of making and using same | |
HK1258765A1 (en) | Therapeutic compounds, compositions and methods of use thereof | |
ZA201807436B (en) | Tobacco leaf extract and use thereof for the treatment of tobacco addiction | |
HK1259196A1 (en) | Delayed-release formulations, methods of making and use thereof | |
HK1226914A1 (en) | New non-tobacco cigarette and its preparation |